mediators and enzymes and interact with structural cells in the airways, lung parenchyma, and pulmonary vasculature. The wide variety of inflammatory mediators that have been shown to be increased in patients with COPD attract the inflammatory cells from the circulation (chemotactic factors) and amplify inflammatory process (proinflammatory cytokines).
killer cells, they play pivotal role in cancer development. MDSCs facilitate cancer cell invasion and intravasation by secreting multiple proteolytic enzymes, including matrix metalloproteinases, which are necessary for extracellular matrix degradation and disruption of endothelial cadherins, adhesion proteins, or the basement membrane of vessels. Epithelial -mesenchymal transition (EMT) is one of the steps for dissemination of cancer cells. When cancer cells undergo EMT, they lose epithelial markers and gain mesenchymal phenotypes. Granulocyte-like MDSCs induce EMT in cancer cells using transforming growth factor β, epidermal growth factor, and hepatocyte growth factor. On the other hand, MDSCs also contribute to mesenchymal -epithelial transition of cancer cells by secreting versican. This function of MDSCs supports cancer cells in colonizing at metastatic niche. 9 In summary, MDSCs are implicated in human pathological conditions including some cancers, inflammatory diseases, and also lung diseases. [10] [11] [12] [13] It is known that smoking, the main risk factor for COPD, upregulates and activates circulating MDSCs in patients with COPD but not in smokers with normal lung function.
14 In patients with COPD, the activation of MDSCs is accompanied by downregulation of the T -cell receptor ζ chain expression.
14 In addition, MDSCs were shown to be elevated in the bone marrow, spleen, and lungs after a 4 -month exposure to cigarette smoke, while this was paralleled by a decreased number of pulmonary dendritic cells. 15 However, these phenotypic MDSCs lacked immune suppressive activity, and thus were not bona fide MDSCs. 13, 15 In a further study, blood MDSC levels were also increased in patients with COPD and correlated with elevated levels of T regs , which is in agreement with studies that suggested reciprocal control of these 2 cell types. 16 In summary, these studies suggest that the accumulation of MDSCs in patients with COPD may underlie the blunted immune response observed in this disease. 13, 16 The occurrence of circulating MDSCs in inflammatory process in COPD has been relatively well documented, but its clinical meaning in COPD has not been determined yet. There have been a few reports on the prevalence of these cells in systemic inflammatory process in COPD, 2,14,16,17 and only one study on the prevalence of MDSCs in the lung microenviroment has been published.
18
The aims of this study were to confirm the presence of MDSCs in peripheral blood (PB) and lung environment using bronchoalveolar lavage (BAL) and to determine their relationship with clinical parameters in patients with COPD.
PAtIEnts And mEthods study population
The study was conducted in the Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, Poznań Poland. It included 64 patients (49 men, 15 women) diagnosed with COPD according to the 2010 criteria of the Global Initiative for Lung Disease pathologically activated CD11b +
Ly6CloLy6G
+ immature granulocytes, D11b + Ly6ChiLy6G − monocytes, and a small proportion of myeloid precursors. In humans predominantly, the immunophenotype of MDSCs is most commonly defined as CD14 -CD11b + or cells expressing a common myeloid cells marker, CD33 + , but not expressing the mature myeloid cell marker, the MHC class II molecules, HLA -DR, also markers of lymphoid cells (Lin -1: CD3, CD14, CD16, CD19, CD20, and CD56). 3 The main characteristic of these cells is their potent ability to suppress T -cell function. Inhibition of T -cell function by MDSCs may be mediated by the induction of regulatory T cells (T regs ) or by anti -inflammatory cytokines such as transforming growth factor β and interleukin 10. It may also involve the metabolism of L -arginine by arginase 1 or inducible nitric oxide synthase. [3] [4] [5] [6] In addition, MDSCs promote tumor progression through a number of different immunological mechanisms.
6-8 Because of the ability of MDSCs to suppress both adaptive and innate immunities mainly through direct inhibition of cytotoxic functions of T cells and natural Exercise capacity was measured using the distance achieved in a 6 -minute walk test (6MWT). 20 An arterial blood gas analysis was performed. Arterial blood samples (1 ml) were obtained from the patients' radial artery, after 5 -minute rest in the sitting position.
blood samples Peripheral blood samples were collected into EDTA tubes (9 ml) for cytometric immunophenotyping, while blood samples collected into tube without anticoagulant (9 ml) were centrifuged at 2500 rpm for 10 minutes at 4°C. The obtained serum samples were frozen immediately at −70°C for subsequent investigations.
Fiberoptic bronchoscopy and bronchoalveolar lavage Only the patients undergoing routine fiberoptic bronchoscopy for diagnostic purposes were enrolled to the study. BAL fluid (BALF) samples were collected according to international guidelines. 21, 22 Topical lignocaine and intravenous fentanyl and propophol anesthesia were used. A special effort was made to use as low dose of lignocaine as possible. 23, 24 The bronchoscope was wedged in the segmental or subsegmental bronchus of the middle lobe. The bronchus was lavaged with 50 -ml aliquots of sterile saline solution at a temperature of 37°C, and then the fluid was aspirated. Two further 50 -ml aliquots of saline solution were instilled and aspirated in the same way.
22,23,25-28
Immunophenotypic assessment Fresh unfixed cells from BALF and PB were immunophenotyped using a flow cytometer. The evaluation of antigenic determinants characteristic for MDSC populations was performed using monoclonal antibodies directly conjugated with fluorochromes (GOLD), 1 who had a relevant history confirmed with a postbronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity (FEV 1 /FVC) of less than 0.7. All patients were older than 40 years and were current (23 patients) or former smokers (41 patients). Patients with other pulmonary disorders, such as asthma, tuberculosis, pulmonary thromboembolism, or interstitial pulmonary lesions, and with contraindications to fiberoptic bronchoscopy or pulmonary function tests, were excluded. A chest computed tomography was performed in all patients to identify individuals with coexisting lung cancer. No lesions suggesting malignancy were visualized, so only patients with COPD and without coexisting lung cancer were enrolled to the study.
All participants gave written informed consent to take part in the study, and approval from the Ethics Committee at the Poznan University of Medical Sciences was obtained. The characteristics of the study population are presented in tAbLE 1.
Pulmonary function tests Spirometry and body plethysmography were performed and the diffusion capacity of carbon dioxide (DL CO ) was measured by an experienced technician using a Master Screen Body/Diffusion Jaeger device (Erich Jaeger GmbH, Hoechberg, Germany). Spirometry was performed 15 to 30 minutes after the inhalation of a short -acting bronchodilator. The results were shown as % predicted. The airflow limitation was defined as postbronchodilator FEV 1 /FVC ratio of less than 0.70. The severity of airflow limitation was divided into 4 grades (1, mild; 2, moderate; 3, severe; and 4, very severe).
1 The BODE index (B, BMI; O, obstruction; D, dyspnea; and E, exercise) was calculated.
19 Dyspnea was assessed using the Modified British Medical Research Council (mMRC) Questionnaire. Two patients reported a score of 0; 13 patients, a score of The results are shown in tAbLE 3 and Supplementary material online ( Figures S1 and S2) . In PB, no significant correlations were found between the percentage of MDSCs among all leukocytes or among MCs and all analyzed parameters.
The results are presented in tAbLE 4.
dIscussIon The presence of MDSCs was first described in animal models and patients with advanced stages of cancer, but was recently found also in patients with early cancer. By suppressing the protective immune response to malignant cells, they may promote the progression of the tumor and the development of metastasis.
29-32
However, there is strong evidence that these cells are also increased and play a regulatory role in the immune responses in bacterial and parasitic infections, acute and chronic inflammation, autoimmunity, traumatic stress, surgical sepsis, and transplantation. [33] [34] [35] MDSCs were shown to be an inherent part of chronic inflammation, so it was tempting to speculate that they may be directly involved in the chronic inflammatory process such as COPD. 13, 35 There are only a few reports assessing the occurrence of circulating MDSCs in the blood of patients with COPD and only one in BALF.
18 For this reason, we attempted to assess the presence of MDSCs not only in blood but also in the bronchial tree, the site of local inflammatory process in COPD. It could be the reason why our study results were slightly different from the results of other researchers.
The most difficult task was to define the immunophenotype of the MDSCs. They are generated from a pool of myeloid progenitor cells that have failed the differentiation into mature cells, and for this reason do not express HLA -DR molecules. MDSCs express markers that are common for cells of myeloid origin. They are positive for CD11b and CD33, and negative for markers characteristic for lymphoid cells, which may be distinguished by use of antibodies Lin1 cocktail. (FIGurE 1) . The samples for analysis were prepared using flow cytometry in the following manner: briefly, initial preparation of BALF samples comprised sterile filtration to remove any mucus, blood clots, and tissue fragments, and concentration of the cells through centrifugation for 10 minutes at 1800 rpm. Resultant supernatants were removed, frozen, and allocated for the evaluation of the concentration of the soluble mediators in further analyses. Antibodies were added to the cell pellets from BALF as well as to PB samples: 5 µl of each antibody per 2 × 10 5 -1 × 10 6 of cells in a sample. Negative controls were samples without added antibodies. Cells were incubated with antibodies for 15 minutes in the dark. In the next step, erythrocyte residues were lysed using 2 ml of lysing solution (BD Biosciences, San Jose, California, United States). Lysis was stopped by adding phosphate buffer saline solution after 10 minutes. Finally, all lysed residues, morphotic particles, and soluble proteins were washed out by double centrifugation for 5 minutes at 1500 rpm. Appropriately stained cells were analyzed using a FACS Canto flow cytometer (BD Biosciences), and the results were processed using the FACS Diva software (BD Biosciences). Up to 50 000 events of each sample were collected. The percentage of positive cells was assessed.
statistical analysis A statistical analysis was conducted using the Statistica 10.0 program (StatSoft, Inc., Tulsa, Oklahoma, United States). All parameters were checked for compatibility to the normal distribution using the Shapiro-Wilk test. A P value of less than 0.05 was considered significant. Results were shown as mean ± standard errors of the mean. To compare the percentage of MDSCs in PB and BALF, the MannWhitney test was used. To assess the presence of a relationship between the percentage of MDSCs in BALF and PB and the clinical parameters, the Pearson correlation coefficient was used.
rEsuLts The study showed a significant difference between the percentages of MDSCs evaluated in PB and BALF. The percentage of MDSCs in BALF was lower than that in PB. The percentage of MDSCs among mononuclear cells (MCs) assessed in BALF was also lower than that in PB. function was significantly higher than that in former smokers, indicating that tobacco smoking is associated with an increased number of circulating MDSCs. Former smokers with COPD maintained similar proportions as current COPD smokers. The authors did not find any significant relationship between the proportion of circulating MDSCs and the severity of airflow limitation in patients with COPD. We also did not observe a significant correlation between the percentage of circulating MDSCs among all leukocytes and among MCs and the results of pulmonary function tests. On the other hand, our results are in line with those of Tan et al. 17 They assessed proportions of MDSCs in PBMCs isolated from patient with stable COPD, smokers with no evidence of COPD, and healthy nonsmokers. Patients with COPD showed increased systemic immune activation but the proportions of MDSCs were similar to those in controls. We also observed no correlation between circulating and airway MDSCs and smoking history. In the available literature, we found only However, our research showed a significant correlation between MDSCs assessed in BALF and the severity of airflow limitation. One of the important findings of our study is that we did not find any correlation between smoking history and MDSCs. It may indicate that airway MDSCs may play a crucial role in local inflammation in COPD independently of cigarette smoking and may aggravate inflammation with the severity of bronchial obstruction. Future studies are necessary and should focus on explaining the role of MDSCs in inflammatory process in COPD.
one study in which BALF was used to identify and characterize human airway MDSCs in patients with COPD. Deshane et al 18 assessed BALF from 8 patients with moderate COPD, 10 healthy individuals, and 9 patients with mild asthma. The authors found that the proportions and numbers of MDSC subsets and their different functional profiles discriminate patients with mild asthma from those with COPD, and both disease groups from healthy individuals. This suggests a critical role for this myeloid lineage cells in the pathogenesis of asthma and COPD. The authors did not assess the correlation between airway MDSCs, pulmonary function tests, and other clinical parameters. 18 In our study, we confirmed the presence of airway MDSCs and also found the relationship between the number of these cells and the degree of airway obstruction.
It is known that hypoxia is a common feature of solid tumors. 37 Hypoxic zones in tumors attract immunosuppressive cells such as MDSCs. Noman et al 38 proved that the tumor microenvironment plays a role in the regulation of PD -L1 surface expression on MDSCs. As hypoxia is one of the major components of tumor microenvironment, they tested the effect of hypoxia on the expression of immune checkpoint receptors (PD -1 and CTLA -4) and their respective ligands (PD -L1, PD -L2, CD80, and CD86) on MDSCs. Hypoxia dramatically and significantly increased the percentage of PD -L1 + MDSCs isolated from the spleen in B16 -F10 and LLC tumor -bearing mice. 38 Similar results were reported by Corzo et al. 39 Hypoxia via HIF -1α dramatically alters the function of MDSCs in the tumor microenvironment and redirects their differentiation toward tumor -associated macrophages, hence providing a link between different MDSCs in the tumor microenvironment. We did not identify any study concerning the relationship of hypoxia and MDSCs in humans, especially in patients with COPD. The results of our study only partially correlate with the results of the above authors. The percentage of MDSCs among lung MCs negatively correlated with airflow limitation parameters. The significant negative correlation with FEV 1 , RV/TLC, and DL CO may indirectly prove that local inflammatory process is connected also with airway obstruction. It may promote worse oxygenation. Our study results indicated a significant correlation between lung MDSCs and PaO 2 and SaO 2 , but further studies explaining this relationship are needed.
In conclusion, there are still more questions than answers about MDSCs and their role in inflammatory process in COPD. The limitation of the current study is the absence of healthy control group. This study had a cross -sectional design. We concentrated on BALF collection and clinical parameters assessment only in patients with COPD. The results confirm that MDSCs occur in the lung microenvironment and PB in patients with COPD. The number of these cells may not be influenced by smoking history. It may suggest that these cells are involved in local inflammatory
